comparemela.com

Page 10 - Klaus Sindahl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hansa Biopharma AB recognizes a write-up of SEK 1 430 billion in intangible assets related to Idefirix in the financial

LUND, Sweden, July 4, 2023 /PRNewswire/ Hansa Biopharma AB (publ.) (Nasdaq Stockholm: HNSA), a pioneer in.

United kingdomPrnewswire hansa biopharmaStephanie kenneyKlaus sindahlEuropean unionKhansa groupNasdaq stockholmSwedish annual accounts actHansa biopharmaFenix advisoryAbuse regulationInvestor relationsmCorporate affairsm

Hansa Biopharma AB recognizes a write-up of SEK 1 430 billion in intangible assets related to Idefirix in the financial statements of the parent company

/PRNewswire/ Hansa Biopharma AB (publ.) (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announces today that, in.

United kingdomKlaus sindahlPrnewswire hansa biopharmaStephanie kenneyEuropean unionKhansa groupVp global corporate affairsNasdaq stockholmSwedish annual accounts actHansa biopharmaFenix advisoryAbuse regulation

Novo Nordisk, Banco Santander and Unilever among winners at IR Magazine Awards – Europe 2023

A packed ballroom of European IR professionals in London erupted in cheers and applause for all the outstanding nominees in the

Czech republicUnited statesUnited kingdomComunidad autonoma de catalunaCity ofMike allenScandinavian fredrik bergeHansa biopharmaBalfour beattyGervais williamsRoz fernandezSimon gleadhillMadeleine szeluchKlaus sindahlBanco santanderAker solutions

Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

LUND, Sweden, June 1, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained

Region flamandeStephanie kenneyHansa biopharmaPrnewswire hansa biopharmaDirk kuypersKlaus sindahlDepartment of nephrologyUniversity hospitals leuvenEuropean unionEuropean medicines agency ema priorityRenal transplantation programVp global corporate affairsEuropean medicines agencyNasdaq stockholmHuman leukocyte antigensProduct characteristics

Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it.

Region flamandeHansa biopharmaKlaus sindahlDirk kuypersStephanie kenneyUniversity hospitals leuvenEuropean unionRenal transplantation programVp global corporate affairsDepartment of nephrologyEuropean medicines agency ema priorityEuropean medicines agencyNasdaq stockholmHuman leukocyte antigensProduct characteristicsEnd stage renal disease

vimarsana © 2020. All Rights Reserved.